Literature DB >> 18399897

Two year follow-up of immunological response in mite-allergic children treated with sublingual immunotherapy. Comparison with subcutaneous administration.

Cristina Antúnez1, Cristobalina Mayorga, José Luis Corzo, Antonio Jurado, María José Torres.   

Abstract

Although the efficacy of allergen-specific sublingual immunotherapy (SLIT) is now accepted, the underlying mechanisms remain elusive. Such mechanisms are better documented in the case of subcutaneous immunotherapy (SCIT). In order to understand the T-lymphocyte response in patients receiving SLIT, we compared children with respiratory disease monosensitized to Dermatophagoides pteronyssinus receiving SLIT or SCIT over a 2-yr period. Peripheral blood was obtained before beginning immunotherapy, and after 3 months, 1 yr and 2 yr. Total IgE, specific IgE and IgG4 to D. pteronyssinus were determined in serum. T-cell markers (CD3, CD4, CD8, CD25) and intracellular cytokine production (TNF-alpha, IL-2, IL-4 and IFN-gamma) were determined in peripheral blood mononuclear cells (PBMC) by flow cytometry. No differences between SCIT and SLIT were detected in the clinical variables or in the subjective evaluation. Although an increase in specific IgE and IgG4 was only detected in SCIT, a significant decrease in the specific IgE/IgG4 ratio was found in both groups. SCIT and SLIT experienced an increase in the CD4/CD8 ratio over time, but an increase in the CD4(+)CD25(+) and a decrease in the CD8(+)CD25(+) subsets were only found with SCIT. A slight shift from a Th2 to a Th1 pattern, measured by the IFN-gamma/IL-4 ratio, was only detected in the CD4 T cells with SCIT. A decrease in both groups was found in TNF-alpha and IL-2 production over time. Children with respiratory allergic diseases receiving SCIT or SLIT had a different immunologic response in peripheral blood during treatment, though the clinical improvement was similar. Whether SLIT induces a mucosal protective response should be studied.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18399897     DOI: 10.1111/j.1399-3038.2007.00604.x

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN: 0905-6157            Impact factor:   6.377


  13 in total

1.  Sub-lingual immunotherapy: world allergy organization position paper 2009.

Authors:  G Walter Canonica; Jean Bousquet; Thomas Casale; Richard F Lockey; Carlos E Baena-Cagnani; Ruby Pawankar; Paul C Potter; Philippe J Bousquet; Linda S Cox; Stephen R Durham; Harold S Nelson; Giovanni Passalacqua; Dermot P Ryan; Jan L Brozek; Enrico Compalati; Ronald Dahl; Luis Delgado; Roy Gerth van Wijk; Richard G Gower; Dennis K Ledford; Nelson Rosario Filho; Erkka J Valovirta; Osman M Yusuf; Torsten Zuberbier
Journal:  World Allergy Organ J       Date:  2009-11-19       Impact factor: 4.084

Review 2.  T-cell responses induced by allergen-specific immunotherapy.

Authors:  E Maggi
Journal:  Clin Exp Immunol       Date:  2010-04-09       Impact factor: 4.330

Review 3.  Subcutaneous and sublingual immunotherapy in children: complete update on controversies, dosing, and efficacy.

Authors:  Désirée Larenas-Linnemann
Journal:  Curr Allergy Asthma Rep       Date:  2008-11       Impact factor: 4.806

Review 4.  Current immunological approaches for management of allergic rhinitis and bronchial asthma.

Authors:  Deepsikha Srivastava; Naveen Arora; Bhanu Pratap Singh
Journal:  Inflamm Res       Date:  2009-03-31       Impact factor: 4.575

5.  Sublingual immunotherapy: World Allergy Organization position paper 2013 update.

Authors:  Giorgio Walter Canonica; Linda Cox; Ruby Pawankar; Carlos E Baena-Cagnani; Michael Blaiss; Sergio Bonini; Jean Bousquet; Moises Calderón; Enrico Compalati; Stephen R Durham; Roy Gerth van Wijk; Désirée Larenas-Linnemann; Harold Nelson; Giovanni Passalacqua; Oliver Pfaar; Nelson Rosário; Dermot Ryan; Lanny Rosenwasser; Peter Schmid-Grendelmeier; Gianenrico Senna; Erkka Valovirta; Hugo Van Bever; Pakit Vichyanond; Ulrich Wahn; Osman Yusuf
Journal:  World Allergy Organ J       Date:  2014-03-28       Impact factor: 4.084

6.  Synthesized OVA323-339MAP octamers mitigate OVA-induced airway inflammation by regulating Foxp3 T regulatory cells.

Authors:  Wen Su; Wenwei Zhong; Yanjie Zhang; Zhenwei Xia
Journal:  BMC Immunol       Date:  2012-07-06       Impact factor: 3.615

7.  Efficacy of sublingual immunotherapy versus subcutaneous injection immunotherapy in allergic patients.

Authors:  Diego Saporta
Journal:  J Environ Public Health       Date:  2012-02-20

8.  Sublingual immunotherapy in asthma does not influence lymphocyte sensitivity to Fas stimulation.

Authors:  Olga Ciepiela; A Zawadzka-Krajewska; I Kotula; M Wasik; U Demkow
Journal:  Eur J Med Res       Date:  2010-11-04       Impact factor: 2.175

9.  Differential Plasma-cell evolution is linked with Dermatophagoides pteronyssinus immunotherapy response.

Authors:  Tahia D Fernández; Enrique Gómez; Inmaculada Doña; Paloma Campo; Carmen Rondon; Miguel Gonzalez; Francisca Gomez; Francisca Palomares; Maria Salas; Miguel Blanca; Cristobalina Mayorga; Maria J Torres
Journal:  Sci Rep       Date:  2015-09-29       Impact factor: 4.379

10.  Characteristics and management of sublingual allergen immunotherapy in children with allergic rhinitis and asthma induced by house dust mite allergens.

Authors:  Florence Trebuchon; Michèle Lhéritier-Barrand; Marie David; Pascal Demoly
Journal:  Clin Transl Allergy       Date:  2014-04-29       Impact factor: 5.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.